SPECIAL NOTICE
A -- NCI OA Special Notice of Subcontract Opportunity at the Frederick National Laboratory for Cancer Research
- Notice Date
- 1/13/2016
- Notice Type
- Special Notice
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- S16-100
- Point of Contact
- SBO Help Desk,
- E-Mail Address
-
NCIOASupport@centeva.com
(NCIOASupport@centeva.com)
- Small Business Set-Aside
- N/A
- Description
- National Institutes of Health, National Cancer Institute, Frederick National Laboratory for Cancer Research Opportunities-Special Announcements: Request For Information (RFI): Innovative Solutions for the Examination of the Utility of Interleukin-27 (IL-27) and/or Interleukin-15 (IL-15) for inhibition of HIV replication both In Vitro and In Vivo This Special Notice is not a formal Invitation for Bid (IFB), Request for Proposal (RFP), Request for Quotation (RFQ) nor any type of solicitation for offers. In accordance with FAR 15.201(d), this special notice is intended FOR INFORMATIONAL PURPOSES ONLY in order to: 1) publicize the requirements of the Frederick National Laboratory for Cancer Research (FNLCR); and 2) increase participation by qualified HUBZone small business, small, small disadvantaged, women-owned small business, veteran-owned small business and service-disabled veteran-owned small business concerns, as applicable. The FNLCR is a Government-Owned Contractor-Operated (GOCO) Federally Funded Research and Development Center (FFRDC) located at Fort Detrick, Maryland. The FNLCR partners with university, government, and corporate scientists to speed the translation of laboratory research into new diagnostic tests and treatments for cancer and AIDS. FNLCR is a multi-program laboratory currently operated by Leidos Biomedical Research Inc. for the National Cancer Institute (NCI) under Prime Contract No. HHSN261200800001E, which provides Operations and Technical Support (OTS) for the Frederick National Lab. The Government assumes no liability for reimbursement for any effort or associated costs to respond, nor for any information provided as a result of this notice as no information is being requested. Please be advised that any submissions provided despite the aforementioned notice that no information is requested become Government property and will not be returned, nor will there be any ensuing discussions or debriefings of any responses. Responses submitted to this notice are not offers and cannot be accepted by the U.S. Government to form a binding contract. It is the responsibility of the interested parties to monitor this site and any sites referenced herein for additional information pertaining to business opportunities with the FNLCR, if any. Research supported and conducted by NIAID strives to understand, treat, and ultimately prevent the myriad of infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Clinical Research (DCR) supports clinical research to control and prevent diseases caused by virtually all infectious agents. This includes basic and applied research to develop and evaluate therapeutics, vaccines, and diagnostics. As the leading U.S. government institute for HIV/AIDS and other infectious disease (ID) research, NIAID is committed to conducting the research necessary to successfully end the fight against HIV/AIDS and combat emerging and re-emerging ID. The DCR research support portfolio includes the oversight of select clinical research projects involving investigational and marketed products and agents. LBRI plays a significant role in many of these clinical research projects by providing project management, regulatory, clinical trials management, laboratory, and programmatic support (i.e., IL-15 Project, Southeast Asia Clinical Research Network, Emerging and Re-emerging Infectious Diseases, Viral Hemorrhagic Fevers, Respiratory and Non-Respiratory Illnesses). Examination IL-15 Promoting basic research and development (R&D) is essential to the advancement of scientific discovery. DCR is currently supporting a R&D initiative for the development and testing of IL-15, which may be beneficial as an immune-based therapy for HIV infection. DCR recognizes the value of investing in basic R&D and continues to expand its research portfolio to include R&D of therapeutics, vaccines, and diagnostics. IL-15 is a cytokine; cytokines are small proteins that are secreted by specific cells of the immune system and carry signals locally between cells. The IL-15 cytokine induces proliferation and differentiation of cytotoxic cells whose principal role is to kill virally infected or cancer cells. The NIAID requires the analysis of IL-15 or similar as part of the initial evaluation of the utility of IL-15 or similar cytokines for the potential clinical safety and efficacy in treating patients infected with HIV or other infectious agents. This analysis will also include any cytokines that may be related to or perturbed in response to IL-15 in Vivo or in Vitro. The anticipated length of this project will be 2-5 years in duration and may support a portfolio of studies. Phenotypic and molecular testing of cells, tissues, and/or infectious agents obtained from small animal model or patients will include, but not limited to, flow cytometry, cell sorting, genetic sequencing, virus isolation, and characterization may be requested. Detailed analysis of the data produced by such testing will also be required. LBRI is seeking innovative solutions for the examination of the utility of IL-15 for inhibition of HIV replication both In Vitro and In Vivo. These innovative solutions should be described in detail and scope. Submission Details for IL-15 : Interested parties are encouraged to respond to this Request for Information S16-100 and provide the following information. Interested parties may respond to both the IL-15 and IL-27, requests or one or the other. Please specify in your response if you are responding to one or the other, or both. 1.Responding Organization Name and Contact Information to include: a.Company Address b.Name of General Company Point of Contact with Contact Information c.Name of Company's Contracting Office Point of Contact with Contact information d.Company Size and Status under NAICS Code 541512 2.A detailed description of the innovative solution(s) for the examination of the utility of IL-15 for inhibition of HIV replication both In Vitro and In Vivo. 3.Examples of relevant past projects that are similar in scope and shall include the following for each project: a.Name of Project b.Period of performance c.Cost/Budget d.Agreement type e.Customer supported f.Description of Project, including the intended scientific goals and the outcomes that followed g.Company's Role in the Project 4.The response shall be no longer than 10 pages for IL-15 and 10 pages for IL-20 for a total of no more than 20 pages. Responses shall not contain any confidential or proprietary information. Examination IL-27 Promoting basic research and development (R&D) is essential to the advancement of scientific discovery. DCR is currently supporting a R&D initiative for the development and testing of IL-27, which may be beneficial as an immune-based therapy for HIV infection. DCR recognizes the value of investing in basic R&D and continues to expand its research portfolio to include R&D of therapeutics, vaccines, and diagnostics. DCR intends to launch this project with an initial study involving IL-27; however, similar cytokines could be studied if interesting scientific findings are discovered as part of this initial project. IL-27 is a heterodimeric cytokine that preferentially inhibits HIV-1 replication in monocyte derived macrophages (MDMs), one of the suspected reservoirs for HIV infection. IL-27 significantly induces interferon-related antiviral genes in MDMs and has been shown capable of inhibiting SIV infection in non-human primate MDMs. The anticipated length of this project will be 2-5 years in duration and may support a portfolio of studies. The NIAID requires the analysis of IL-27 or similar as part of the initial evaluation of the utility of IL-27 or similar cytokines for the potential clinical safety and efficacy in treating patients infected with HIV or other infectious agents. This analysis will also include any cytokines that may be related to or perturbed in response to IL-27 in Vivo or in Vitro. Phenotypic and molecular testing of cells, tissues, and/or infectious agents obtained from small animal model or patients will include, but not limited to, flow cytometry, cell sorting, genetic sequencing, virus isolation, and characterization may be requested. Detailed analysis of the data produced by such testing will also be required. LBRI is seeking innovative solutions for the examination of the utility of IL-27 for inhibition of HIV replication both In Vitro and In Vivo. These innovative solutions should be described in detail and scope. Submission Details for IL-27 : Interested parties are encouraged to respond to this Request for Information S16-100 and provide the following information. Interested parties may respond to both the IL-27 and IL-15 requests, or one or the other. Please specify in your response if you are responding to one or the other, or both. 5.Responding Organization Name and Contact Information to include: a.Company Address b.Name of General Company Point of Contact with Contact Information c.Name of Company's Contracting Office Point of Contact with Contact Information d.Company Size and Status under NAICS Code 541512 6.A detailed description of the innovative solution(s) for the examination of the utility of IL-27 for inhibition of HIV replication both In Vitro and In Vivo. 7.Examples of relevant past projects that are similar in scope and shall include the following for each project: a.Name of Project b.Period of performance c.Cost/Budget d.Agreement type e.Customer supported f.Description of Project, including the intended scientific goals and the outcomes that followed g.Company's Role in the Project 8.The response shall be no longer than 10 pages for IL-15 and 10 pages for IL-20 for a total of no more than 20 pages. Responses shall not contain any confidential or proprietary information. Contact Information : Responses shall be emailed to Calvin Proffitt at calvin.proffitt@fnlcr.nih.gov by 2 p.m. Eastern Time, January 29, 2016. Disclaimer : This RFI is solely for informational purposes and does not constitute a solicitation. All information received will be handled as Proprietary information. Responders are solely responsible for all expenses associated with their respective response.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/S16-100/listing.html)
- Record
- SN03990631-W 20160115/160113234923-1407a0f09c5e1ccbe0372155ed6a4bc6 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |